十堰闷做什么检查钦州心脏检查需要注意什么,阜阳体检医院哪家比较专业,马鞍山常浑身无力是怎么回事,襄阳身无力是,潮州体检医院哪家比较专业,营口检哪里比较好,渭南般健康体检都检查哪些项目

SAN FRANCISCO, June 13 (Xinhua) -- Google on Monday confirmed that it had signed an agreement to buy Admeld, an on-line advertising optimization firm, in a deal seen as the Internet search giant's latest move to bolster its on-line display ad business.Admeld, launched in 2007 and headquartered in New York City, has developed a service that can help on-line publishers manage their ad space more efficiently and profitably.Admeld now has more than 500 customers worldwide, among them are FOX News, IDG TechNetwork, Discovery and The Weather Channel, according to information posted on its website."By combining Admeld's services, expertise and technology with Google's offerings, we're investing in what we hope will be an improved era of flexible ad management tools for major publishers, " Neal Mohan, Google's vice president of display advertising, said in a blog post announcing the deal."We believe that this investment will be an important step to help on-line publishers, and will further improve and grow the display advertising industry as a whole," Mohan noted.On-line display ads usually appear in forms that consist of images and may be interactive. According to the Interactive Advertising Bureau, a U.S. trade association, display-related on- line ad revenue in the United States totaled nearly 10 billion U.S. dollars in 2010.Financial terms of the deal were not disclosed by the two companies. TechCrunch, a technology blog site, has reported that Google paid around 400 million dollars.

BEIJING, Sept. 26 (Xinhuanet) -- Although it is home to traditional Chinese medicine (TCM), China must do much more to improve its academic research capacity for acupuncture, a form of TCM, to take the lead worldwide on both the academic and clinical sides.At present, among all academic theses on acupuncture indexed by the Science Citation Index (SCI), a leading world thesis index system, only 5 percent are from the Chinese mainland, according to Wang Linpeng, the director of the acupuncture and moxibustion center of the Beijing Hospital of Traditional Chinese Medicine, which is affiliated with the Capital Medical University.Although Chinese acupuncturists absolutely excel worldwide in clinical practice, "they are not as good as their foreign peers in academic capacity, particularly Western-style research methods and lab experiment design," he told China Daily on Friday during the 2011 International Symposium on Acupuncture. A patient suffering from facial paralysis receives acupuncture treatment at a hospital in Nanjing, the capital of Jiangsu province, on Dec 6, 2010.Studies by TCM practitioners - including acupuncturists - largely focus on their area of specialization, and few are in line with global interest in the medical science that has been proven effective over thousands of years, he said."Chinese TCM practitioners are very good at treating conditions, but they are clumsy at showing how and why it really works in an internationally accepted 'language' and 'manner'," said Gao Sihua, chancellor of the Beijing University of Chinese Medicine."It's especially true in TCM circles, where few Chinese practitioners would regularly follow international academic articles and research trends," Wang said.Measured by the number of articles on acupuncture indexed by SCI, the US and European countries lead globally, he said.

BEIJING, Aug. 12 (Xinhuanet) -- Engineers at the University of Illinois have unveiled novel, skin-mounted electronics whose circuitry bends, wrinkles, and even stretches with skin, according to media reports quoting the Science Friday.The device platform includes electronic components, medical diagnostics, communications, and human-machine interfacing on a patch so thin and durable that it can be mounted to skin much like a temporary tattoo, the jounral described.What's more, the engineers demonstrated the invention across a wider range of components, including LEDs, transistors, wireless antennas, sensors, and conductive coils and solar cells for power."We threw everything in our bag of tricks onto that platform, and then added a few other new ideas on top of those to show that we could make it work," said engineering professor John A. Rogers in a news release.

BEIJING, Sept. 25 (Xinhua) -- As China's economy has soared to the second place in the world, the country's scientific strength has also surged -- if only measured by the numbers.Chinese researchers published more than 1.2 million papers from 2006 to 2010 -- second only to the United States but well ahead of Britain, Germany and Japan, according to data recently published by Elsevier, a leading international scientific publisher and data provider. This figure represents a 14 percent increase over the period from 2005 to 2009.The number of published academic papers in science and technology is often seen as a gauge of national scientific prowess.But these impressive numbers mask an uncomfortable fact: most of these papers are of low quality or have little impact. Citation per article (CPA) measures the quality and impact of papers. China's CPA is 1.47, the lowest figure among the top 20 publishing countries, according to Elsevier's Scopus citation database.China's CPA dropped from 1.72 for the period from 2005 to 2009, and is now below emerging countries such as India and Brazil. Among papers lead-authored by Chinese researchers, most citations were by domestic peers and, in many cases, were self-citations."While quantity is an important indicator because it gives a sense of scientific capacity and the overall level of scientific activity in any particular field, citations are the primary indicator of overall scientific impact," said Daniel Calto, Director of SciVal Solutions at Elsevier North America.Calto attributed China's low CPA to a "dilution effect.""When the rise in the number of publications is so rapid, as it has been in China -- increasing quantity does not necessarily imply an overall increase in quality," said Calto.He noted the same pattern in a variety of rapidly emerging research countries such as India, Brazil, and earlier in places like the Republic of Korea."Chinese researchers are too obsessed with SCI (Science Citation Index), churning out too many articles of low quality," said Mu Rongping, Director-General of the Institute of Policy and Management at the Chinese Academy of Sciences, China's major think tank.SCI is one of the databases used by Chinese researchers to look-up their citation performance. The alternative, Scopus, provides a wider coverage worldwide."Chinese researchers from a wide range of areas and institutions are vying for publication, as it is a key criterion for academic appraisal in China, if not the only one. As a result, the growth of quality pales in comparison to that of quantity," said Mu, an expert on China's national science policy and competitiveness.On the other hand, China also falls behind the United States in multidisciplinary research, which is a core engine for scientific advance and research excellence.From 2006 to 2010, China published 1,229,706 papers while the United States churned out 2,082,733. According to a new metric introduced by Elsevier's Spotlight research assessment solution, China generated 885 competencies while the United States had 1,817.In other words, China's total research output is more than half that of the United States, while the number of competencies showing China's strength in multidisciplinary research is less than half that of the United States.Cong Cao, an expert on China's science and technology, put it more bluntly in an article he wrote: "When the paper bubble bursts, which will happen sooner or later, one may find that the real situation of scientific research in China probably is not that rosy."China has been investing heavily in scientific research and technological development in recent years to strengthen its innovative capacity, The proportion of GDP spent on R&D grew from 0.9 percent in 2000 to 1.4 percent in 2007, according to the World Bank.An IMF forecast in 2010 says China now ranks second globally in R&D spending. The IMF calculates China's R&D expenditure at 150 billion U.S. dollars when based on Purchasing Power Parity, a widely used economic concept that attempts to equalize differences in standard of living among countries.By this measure, China surpassed Japan in R&D spending in 2010.Many see China's huge investment in R&D as the momentum behind the country's explosive increase in research papers."Getting published is, in some ways, an improvement over being unable to get published," Mu said. "But the problem is, if the papers continue to be of low quality for a long time, it will be a waste of resources."In China, academic papers play a central role in the academic appraisal system, which is closely related to degrees and job promotions.While acknowledging the importance of academic papers in research, Mu believes a more balanced appraisal system should be adopted. "This is a problem with science management. If we put too much focus on the quantity of research papers, we leave the job of appraisal to journal editors."In China, the avid pursuit of publishing sometimes gives rise to scientific fraud. In the most high-profile case in recent years, two lecturers from central China's Jinggangshan University were sacked in 2010 after a journal that published their work admitted 70 papers they wrote over two years had been falsified."This is one of the worst cases. These unethical people not only deceived people to further their academic reputations, they also led academic research on the wrong path, which is a waste of resources," Mu said.A study done by researchers at Wuhan University in 2010 says more than 100 million U.S. dollars changes hands in China every year for ghost-written academic papers. The market in buying and selling scientific papers has grown five-fold in the past three years.The study says Chinese academics and students often buy and sell scientific papers to swell publication lists and many of the purported authors never write the papers they sign. Some master's or doctoral students are making a living by churning out papers for others. Others mass-produce scientific papers in order to get monetary rewards from their institutions.A 2009 survey by the China Association for Science and Technology (CAST) of 30,078 people doing science-related work shows that nearly one-third of respondents attributed fraud to the current system that evaluates researchers' academic performance largely on the basis of how many papers they write and publish.Despite rampant fraud, China will continue to inject huge money into science. According to the latest national science guideline, which was issued in 2006 by the State Council, the investment in R&D will account for 2.5 percent of GDP in 2020."If China achieves its stated goal of investing 2.5 percent of its GDP in R&D in 2020, and sustains its very fast economic growth over the next decade, it would quite likely pass the U.S. in terms of total R&D investment sometime in the late 2010s," said Calto, adding that it is also quite likely that at some point China will churn out more papers than the United States.According to Calto, China does mostly applied research, which helps drive manufacturing and economic growth, while basic research only accounts for 6 percent, compared with about 35 percent in Germany, Britain, and the United States, and 16 percent in Japan."In the long term, in order to really achieve dominance in any scientific area, I think it will be necessary to put significant financial resources into fundamental basic research -- these are the theoretical areas that can drive the highest level of innovation," Calto said.

SYDNEY, July 15 (Xinhua) -- The world's first drug to increase life expectancy of people with advanced melanoma has been approved for use in Australia, local media reported on Friday.The breakthrough drug Yervoy got approval from the Therapeutics Good Association (TGA) on Friday amid hopes it could add two years to the life of people with the most lethal form of skin cancer but for whom other treatments have failed, the Australian Associated Press (AAP) said.Clearance for the drug's use in Australia follows similar approvals by the U.S. health regulator in March.Yervoy works by attacking and destroying cancer cells.Patients are hooked up to an intravenous drip once every three weeks for a total of four doses.Professor Peter Hersey, consultant immunologist to the Melanoma Institute Australia, said no other drug had improved survival rates like Yervoy."Not all patients respond to it but those who do have a good chance of living longer than they would have otherwise," Hersey told AAP.While it may improve survival rates, Yervoy can produce side effects from diarrhea and vomiting to serious blood infections and kidney failure.The average survival time for people with advanced melanoma is just six months.A global study of 676 people with melanoma found that 45 percent of patients given Yervoy were still alive after one year, according to AAP.More than 20 percent lived at least two years, with a small number managing to survive for six years.A separate study, published in June, which showed similarly improved survival rates for patients with newly diagnosed advanced melanoma, has raised hopes that Yervoy could be made more widely available.Melanoma is the fourth most common cancer in Australia, with 10, 300 people diagnosed each year.